Q1 FY2027 Financial Results for the Fiscal Year Ending March 2027 (Japan GAAP) [Consolidated]

Overview of Operating Results

Consolidated earnings for the first quarter of the current fiscal year totaled 170 million yen in revenue, down from the previous fiscal year. This primarily reflects costs related to foundational and drug discovery research for pharmaceutical candidates, as well as clinical development expenses for small-molecule drugs, cancer peptide vaccines, and antibody medicines. Consolidated operating loss was 285 million yen, ordinary loss 287 million yen, and net loss attributable to owners of the parent was 288 million yen. By segment, pharmaceutical R&D-related operations recorded an operating loss of 160 million yen, and cancer precision medicine-related operations recorded an operating loss of 17 million yen. The full-year FY2027 earnings guidance will be announced as soon as it is determined; no guidance has been disclosed at this time.

Financial Position and Cash Position

As of the end of the first quarter, total assets were 2,612 million yen, net assets 2,348 million yen. Cash and deposits were 2,326 million yen, comprising the majority of current assets. Total liabilities amounted to 264 million yen, with current liabilities of 217 million yen and long-term liabilities of 47 million yen. There are no material uncertainties regarding the continuity of the company, but note the business model involves substantial R&D expenditures.